Abstract
Historically, chronic pain generally went under-treated for a variety of objective and subjective reasons, including difficulty to objectively diagnose and manage over a long period of time, potential serious adverse effects of commonly available medications, and patient, healthcare and societal concerns over opioid medications. More recently, in an effort to redress the under-treatment of pain, the number of prescriptions of opioid analgesics has risen dramatically. However, paralleling the increased legitimate use has been a concomitant increase in opioid abuse, misuse and diversion. Pharmaceutical companies have responded by developing a variety of opioid formulations designed to deter abuse by making the products more difficult to tamper with. One such product is Remoxy®, an extended-release formulation of the strong opioid oxycodone. We review the efficacy, safety and tolerability of this formulation based on the available published literature.
Original language | English (US) |
---|---|
Pages (from-to) | 231-238 |
Number of pages | 8 |
Journal | Expert Review of Neurotherapeutics |
Volume | 15 |
Issue number | 3 |
DOIs | |
State | Published - Mar 1 2015 |
Keywords
- abuse
- abuse-deterrent
- chronic pain
- opioid
- oxycodone
- Remoxy
ASJC Scopus subject areas
- Clinical Neurology
- General Neuroscience
- Pharmacology (medical)
- General Medicine